Cardiac toxicity of coxibs: mechanisms of development and their prevention

  • O O Yakovleva National Pirogov Memorial Medical University, Vinnytsia, Ukraine
  • A O Zhamba National Pirogov Memorial Medical University, Vinnytsia, Ukraine
  • I O Doroshkevych National Pirogov Memorial Medical University, Vinnytsia, Ukraine
  • T K Vitruk National Pirogov Memorial Medical University, Vinnytsia, Ukraine
Keywords: NSAIDs, selectivity, coxibs, cardiovascular toxicity, evidence-based medicine


Development of highly selective COX-2 inhibitors – coxibs has proved a decreased risk of gastrointestinal toxicity, which was typical for non-selective NSAIDS, according to the evidence-based medicine. But such situation caused an imbalance in the impact on the synthesis of arachidonic acid metabolites: inhibition of COX-2 vasodilatatory prostacyclins and activation of thromboxane synthesis by platelets, which is accompanied by the increase in the frequency of thrombotic complications – myocardial infarctions and strokes. Some meta-analyses have proved this association: the higher is COX-2 inhibitors selectivity – the higher are CV-risks and cardiovascular toxicity of coxibs. Discontinuation or limitation of indications of coxibs, assessment of risk / benefit ratio is recommended in the conditions of comorbidity of CVS pathology, pain syndromes in rheumatology. Drugs of choice are moderately selective COX-2 inhibitors = meloxicam and nimesulide.


Download data is not yet available.


Дядык АИ. Кардиоваскулярные побочные эффекты нестероидных противовоспалительных препаратов: факты, фикции, клиническая значимость. Здоров’я України, 2013; 10: 3–5.

Карпенко ЕА. Нестероидные противовоспалительные препараты и артериальная гипертензия – проблема современной кардиологии. Український науково-медичний молодіжний журнал, 2014; 1 (79): 160–3.

Коксибы: существуют ли преимущества по сравнению с традиционными неселективными НПВП в лечении послеоперационной боли? Здоров’я України, 2014; 4: 27–29.

Сатыбалдыев АМ. Что безопаснее для желудочно-кишечного тракта –коксибы или мелоксикам? Современная ревматология, 2017; 11(1):72–8.

Шостак НА. Нестероидные противовоспалительные препараты – современные аспекты их применения. Клиницист, 2013; 3–4: 53–61.

Back M., Yin L., Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascularrisk in a nation-wide cohort study after the withdrawal of rofecoxib //European Heart Journal, 2012; 33. 1928–33.

Bavry AA., Khaliq A, Gong Y, et al. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease // The American Journal of Medicine, 2011; 124: 614–20.

BEXTRA: valdecoxib tablets. Anaviable at Accessed January 09, 2005.

Bhala N., Emberson J., Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Coxib and traditional NSAID Trialists’(CNT) Collaboration // Lancet, 2013, 31(382): 769–79.

Bhatt D. L. ACCF/ ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group // New Engl. J. Med, 2000, 343(21): 1520–8.

Bresalier RS, Sandler RS, Quan H. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl. J. Med,2005, 352: 1092–102.

Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. Journal of the Royal Society of Medicine, 2006, 99: 132–140.

Cannon C., Curtis S., FitzGerald G, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison // Lancet,2006;18:368:1771–1781.

Capone ML, Sciulli MG, Tacconelli S. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects // J. Am. Coll. Cardiol.,2005;45:1295–301.

Catella-Lawson F, Reilly MP, Kapoor SC. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin // New Engl. J. Med, 2001, 345:1809–817.

Chen YF, Johanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation // Health Technol Assess, 2008, Apr; 12(11):1–278.

de Leest HT, Steen KS, Lems WF, et al. Eradication of Helicobacter pyloridoes not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial// Helicobacter, 2007 Oct;12(5):477–85.

Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison// Lanset, 1999, 354:2106–11.

FitzGerald GA, Patrono C. The coxibs/selective inhibitors of cyclooxygenase-2 // New Engl. J. Med., 2001, 345:433–42.

Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study // Clin.Pharmacol. Ther., 2009, Feb;85(2):190–7. doi: 10.1038/clpt.2008.204.Epub 2008 Nov 5.

Goidstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinalulcer complications with celecoxib, a novel COX-2 inhibitor // Am.J. Gastroenterol., 2000, 95:1681–90.

Gottlieb S. Warning issued over COX2 inhibitors in US and UK // BMJ, 2005,330, 9–14.

Hunt R, Harper S, Watson D, et al. The gastrointestinal safety of the COX-2selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events // Am. J. Gastroenterol., 2003, 98(8): 1725–33.

Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis // Lancet, 2004, 364: 2021–9.

Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term(MEDAL) programme: a randomised comparison // Lancet, 2007, 369:465–73.

Lazzaroni M, Bianchi Porro G. Nonsteroidal anti-inflammatory drug gastropathy and Helicobacter pylori: the search for an improbable consensus //Am. J. Med., 2001, Jan, 8;110(1A): 50S–54S.

Lec TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans // Am. J. Med., 2007,120: 9–16.

McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies // PLoS Med, 2011, 8:1001–98.

Nussmeier NA, Whelton AA, Brown MT. Complications of the COX-2 inhibitors parecoxib and valecoxib after cardiac surgery // New Engl. J. Med, 2005,352:1081–91.

Ott E, Nussmeier NA, Duke PS. Efficary and safety of the cyclooxygenase-2inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery // J. Thorac Cardiovasc. Surg, 2003, 125:1481–92.

Patrono C, Baigent C. Low-dose aspirin, coxibs, and other NSAIDs: a clinical mosaic emerges // Molecular Interventions, 2009, 9:31–9.

Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis // Curr. Med. Res. Opin., 2005, 21(5): 715–22.

Ray WA, Griffin MR, Stein CM. Cardiovascular toxicity of valdecoxib // New Engl. J. Med., 2004, 351:2767.

Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and rick of seriours coronary heart disease // Lancet,2002, 360, р. 1071–3.

Rostom A, Muir K, Dube C. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review // Clin. Gastroenterol. Hepatol., 2007, 5:818–28.

Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT // Annals of Rheumatic Diseases, 2010, 69(8):1459–64.

Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxibvs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial // CelecoxibLong-Term Arthritis Safety Study. JAMA, 2000, 284: 1247–55.

Singh G, Fort JG, Goldstein JL, et al. For the SUCCESS-I Investigators Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-IStudy // Am. J. Med, 2006, 119: 255–66.

Singh G, Miller JD Lee F.H, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey // 2002, 8(15):83–91.

Singh G, Mital A, Triadafiopoulos G. Age – adjusted hospitalization rates for complicated gastric and duodenal ulcers in the US: have COX-2 inhibitors and PPls made any difference // Digestive Disease Week, May 15–20, 2004,New Orlean.

Smale S., Tibbie J., Sigthorsson G, et al. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine // Best Practice & Research Clinical Gastnienterology, 2001, 15(5):723–38.

Solomon S.D., McMurray J.J., Pfeffer M.A, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention // New Engl. J. Med, 2005, 352(11): 1071–80.

Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6randomized placebo-controlled trials. The cross trial safety analysis // Circulation,2008, 117:2104–13.

TARGET: Schnitzer T J. Burmester G. R., Mysler E. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial // Lancet, 2004, 364:665–74.

Topol EJ. Rofecoxib, Merck and the FDA // N. Enge J. Med, 2004, 351,2877–8.

Topol E J. Arthritis medicines and cardiovascular events – “house of coxibs”// JAMA, 2005, 293, 366–8.

White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving Celecoxib: a meta-analysis of randomized clinical trials // American Journal of Cardiology, 2007, 99:91–8.

Yang M, Wang HT, Zhao M, et al. Network meta-analysis comparing relatively selective COX-2 inhibitors versus coxibs for the prevention of NSAID-induced gastrointestinal injury // Medicine (Baltimore),2015, 94(40): 1592–8.

How to Cite
Yakovleva OO, Zhamba AO, Doroshkevych IO, Vitruk TK. Cardiac toxicity of coxibs: mechanisms of development and their prevention. PMJUA [Internet]. 2018Nov.23 [cited 2019Jul.24];3(3):27-2. Available from: